Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03416335 · ClinicalTrials.gov registry record · Phase 1
A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Terminated
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT03416335 is a Phase 1 study that was terminated before completion, run by Sumitomo Pharma America. The registered enrollment target is 36 participants.
The verdict
NCT03416335, a Phase 1 study, was terminated before completion, sponsored by Sumitomo Pharma America.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a multi-center, Phase 1 / 2 clinical study for patients with advanced solid tumors. The study consists of 2 treatment arms - a monotherapy arm and a combination arm. The monotherapy arm has 1 part: Dose Escalation (Part A). The combination arm has Dose Escalation (Part B) only.
Interventions
- DRUG DSP-0509
- DRUG DSP-0509, Pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2022-12-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03416335
The ClinicalTrials.gov registry entry for NCT03416335 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DSP-0509 is the first listed.
NCT03416335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03416335 about?
NCT03416335 is a clinical study titled "A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile". This is a multi-center, Phase 1 / 2 clinical study for patients with advanced solid tumors. The study consists of 2 treatment arms - a monotherapy arm and a combination arm. The monotherapy arm has 1 part: Dose Escalation (Part A). The combination arm has Dose Escalation (Part B) only.
What is the current status of trial NCT03416335?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2018-06-01. Estimated completion is 2022-12-20.
What interventions are being tested in trial NCT03416335?
The interventions under investigation include: DSP-0509 (DRUG), DSP-0509, Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT03416335?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.